Too Many Black Men Are Dying From Prostate Cancer
Prostate cancer remains the second highest cancer-related cause of death in men in the U.S., and there has been a worrisome trend of rising metastatic disease at diagnosis. These facts make it increasingly important that the urological community and the patients we serve turn our attention to ways to overcome these challenges. The Role of […]
ADT Options for Prostate Cancer Come Out Even for Heart Safety
Androgen deprivation therapy (ADT) options for prostate cancer seemed to have a similar impact on the risk of cardiovascular events among people with documented heart disease, according to results from the PRONOUNCE trial, although the study was terminated early due to slow accrual. In 545 men, there was no statistically significant difference in the rate […]
Surveillance for Prostate Cancer Is on the Rise — Do Men Stick It Out?
While the uptake of active surveillance (AS) for low-risk prostate cancer has increased over time, about half of patients eventually discontinue this strategy, according to an observational Canadian population-based study. The use of AS increased from 38% in 2008 to 69% in 2014; however, over this study period, 50.8% of patients discontinued AS and proceeded […]
Can Working Out Slow Prostate Cancer Progression?
Rigorous exercise not only boosted cardiorespiratory fitness, but also improved indicators of prostate cancer biochemical progression in patients undergoing active surveillance, according to results of a randomized trial. Patients participating in a 12-week high-intensity interval training (HIIT) regimen saw an increase in peak oxygen consumption (VO2) — the study’s primary outcome — of 0.9 mL/kg/min, […]
Novel Blood-Based Test Could Bolster MRI-Based Prostate Cancer Screening
Addition of a novel blood test to MRI-targeted biopsy in prostate cancer screening decreased overdetection while maintaining the ability to detect clinically significant cancer, Swedish researchers reported. They found that use of the test — called Stockholm3 — in a screening setting where MRI and targeted biopsies were used, performed at least as well as […]
When Is ADT Right for Biochemically Recurrent Prostate Cancer?
Men with prostate cancer and biochemical recurrence (BCR) who delayed androgen deprivation therapy (ADT) still experienced long survival outcomes, researchers reported. In a retrospective study, men with a prostate-specific antigen doubling time (PSADT) of less than 10 months saw a median metastases-free survival (MFS) of 192 months when they delayed ADT until metastasis, and a […]
Black Prostate Cancer Patients Less Likely to Go Under the Knife During Pandemic
The odds of undergoing surgery for prostate cancer were significantly lower for Black patients compared with white patients during the initial wave of the COVID-19 pandemic, according to a retrospective cohort study. Just 1% of Black men with untreated nonmetastatic prostate cancer underwent prostatectomy from March to May 2020 compared with 26% of white men, […]
Support for MRI-Targeted Biopsy in Prostate Cancer Screening
A prostate cancer screening strategy using MRI with targeted and standard biopsy reduced the detection of clinically insignificant cancers as well as unnecessary biopsies, researchers reported. Such an approach was also as effective as a standard biopsy strategy in detecting clinically significant cancers, said Tobias Nordstrom, MD, PhD, of the Karolinska Institutet in Stockholm, in […]